Andere Sprachen Regen BioPharma, Inc. OTC Markets

Aktien

A3D77B

US75886M4096

RGBPP

Markt geschlossen - OTC Markets Andere Börsenplätze 19:28:14 17.06.2024			% 5 Tage	% 1. Jan.
1.5 ^USD	+48.51%		+19.05%	-36.40%

24.04.	Regen BioPharma, Inc. meldet Ergebnis für das zweite Quartal und die sechs Monate bis zum 31. März 2024	CI
09.02.	Regen Biopharma, Inc. meldet eine vorläufige Patentanmeldung zur Beschleunigung der hämatopoetischen Rekonstitution nach einem Insult oder einer chronischen Erkrankung durch Verabreichung von aus Stammzellen gewonnenen endothelialen Vorläuferzellen oder Endothelzellen an	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Regen BioPharma : Material Event - Form 8-K	29.04.
Regen BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	24.04.
Regen Biopharma, Inc. Files Provisional Patent Application for Accelerating Hematopoietic Reconstitution After an Insult or Chronic Pathology by Administration of Stem Cell Derived Endothelial Progenitor Cells or Endothelial Cells	09.02.
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on February 7, 2024	05.02.
Regen BioPharma, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	19.01.
Regen BioPharma, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	20.11.
Regen BioPharma, Inc. Outlines Future Steps in CAR T Program	14.11.
Regen BioPharma, Inc Receives Second Phase Confirmatory Data on its Duracar CAR-T Cell Therapy Program	25.10.23
Regen Biopharma, Inc. Expects Second Phase of Confirmatory Study Shortly	18.10.23
Regen BioPharma, Inc. issues Message to the Shareholders from the Chairman And Chief Executive Officer	20.09.23
Studies on Regen Biopharma, Inc.'s Duracar Indicate Potential Suppression of Autoimmunity, Company Retains Contract Research Organization to Conduct Additional Confirmatory Studies	19.09.23
Regen BioPharma, Inc. announced that it has received $0.14875 million in funding	12.09.23
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on August 10, 2023	08.08.23
Regen BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	25.07.23
Regen BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	18.04.23
REGEN BIOPHARMA INC : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year (form 8-K)	07.02.23
Regen BioPharma Leverages Exosome Technologies to Broaden its Survivin Cancer Immunotherapy Portfolio	23.01.23
REGEN BIOPHARMA INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)	19.01.23
Regen BioPharma, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022	19.01.23
Regen BioPharma, Inc. Announces Board Appointments	07.12.22

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Regen BioPharma, Inc. OTC Markets

Aktien

A3D77B

US75886M4096

RGBPP

Andere Sprachen

Filter